Today: 2 March 2026
Subscribe
Browse Category

Mergers & Acquisitions 3 October 2025 - 15 October 2025

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros shares soared about 146% on Oct. 15, 2025, closing near $10.11 after Novo Nordisk agreed to license its drug zaltenibart for up to $2.1 billion. Omeros will receive $340 million upfront, with the deal expected to close in Q4. The company will now focus on its lead drug narsoplimab, which is under FDA and EMA review. Analyst targets for Omeros stock range from $9 to $36.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

HOND stock jumped from $18.86 to $24.98 between Oct. 13 and Oct. 15 on heavy volume, ahead of an Oct. 20 shareholder vote on its merger with Terrestrial Energy. The SEC cleared the S-4 registration on Sept. 26, enabling the vote. If approved, the combined company will list on Nasdaq as “IMSR.” Terrestrial’s molten salt reactor technology recently received NRC approval, the first for its kind.
15 October 2025
··
Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro Stock Skyrockets on Flashy Merger Deal – Is This the Cannabis Builder’s Comeback?

Urban-gro, Inc. signed a binding letter of intent on Oct. 14, 2025, to merge with Flash Sports & Media, whose shareholders will own about 90% of the combined company. Urban-gro’s stock surged up to 60% intraday on the news but stayed below Nasdaq’s $1 minimum, leaving its listing in jeopardy. The company faces financial struggles, including defaulting on a $10 million credit line and settling a $1.49 million lawsuit.
14 October 2025
···
Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Astria Therapeutics shares surged up to 50% on Oct. 14, 2025, after BioCryst Pharmaceuticals agreed to acquire the company in a cash-and-stock deal valuing ATXS at about $13 per share. Halper Sadeh LLC announced an investigation into the fairness of the sale. Astria’s lead drug navenibart is in Phase 3 trials for hereditary angioedema, with topline data expected in early 2027.
14 October 2025
···
BlackRock’s GIP Poised for $38B AES Power Grab – AI-Fuelled Demand Sparks Takeover Frenzy

BlackRock Soars: Crypto ETFs, AI Funds and Mega M&A Propel Assets to Record $13.5T

BlackRock posted Q3 2025 adjusted EPS of $11.55 on $6.51 billion revenue, beating estimates, as assets surged to a record $13.46 trillion with $171 billion in net inflows. The firm closed its $6.5 billion HPS deal, completed the ElmTree Funds acquisition, and saw record ETF demand. BlackRock exited the Net Zero Asset Managers Initiative amid political pressure. Shares trade near all-time highs, up 13% year-to-date.
14 October 2025
···
PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (NASDAQ: ELAB) shares surged over 230% pre-market on Oct. 14, briefly topping $13 before settling near $5.20. The stock remains down about 90–99% year-to-date after a reverse split in September. Recent acquisitions include Pacific Sun Packaging and AGA Precision Systems, adding up to $2.4 million in annual revenue. PMGC now focuses on industrial manufacturing alongside its biotech assets.
14 October 2025
··
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive, Inc. (NASDAQ: ASST) stock plunged 32% after-hours on Oct. 10, 2025, following news it registered 1.283 billion insider shares for resale. The company recently agreed to acquire Semler Scientific in an all-stock $1.34 billion deal, adding about 5,800 BTC to its holdings. ASST traded between $0.34 and $13.42 in 2025, hovering near $1.05 after the sell-off. Strive completed its SPAC merger in September.
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics shares surged over 30% to nearly $89 on October 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The company, valued at about $5.4 billion, recently announced positive trial results for its lead drugs and secured major partnerships with J&J and Takeda.
11 October 2025
·····
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics shares surged over 30% to $89.19 on Oct. 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The jump follows positive Phase 2b results for Icotrokinra in ulcerative colitis and recent FDA Breakthrough Therapy Designation for Rusfertide in polycythemia vera.
10 October 2025
···
MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MRM shares surged 22% pre-market Oct. 9 after MOTHER Labs secured Series A funding at a ¥9 billion valuation. In late September, MEDIROM partnered with World to deploy World ID Orb devices in 100 Re.Ra.Ku salons, the largest rollout in Japan. Its REMONY system received Japanese government certification in August and was adopted by the Ground Self-Defense Force. MEDIROM posted 2024 revenue of $52.74M, up 22%.
9 October 2025
·
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent (CFLT) Stock Surges on Takeover Rumors – What’s Next for the Data Streaming Pioneer?

Confluent, Inc. shares surged nearly 20% in pre-market trading October 8 after Reuters reported the company is exploring a sale amid acquisition interest. The stock jumped to around $24.70, near analysts’ average 12-month target, but remains down about 25% year-to-date. Confluent posted Q2 revenue of $282 million, up 20% year-over-year, but is not yet GAAP-profitable. The company trades at a premium, with a ~$7 billion market cap.
8 October 2025
··
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent shares closed at $20.73 on Oct. 7, down 2.49% after six declines in ten sessions, but up 4% over two weeks. The stock is down 26% year-to-date but has gained 6.5% year-over-year. Reuters reports Confluent is exploring a sale, triggering a 19% pre-market rally on Oct. 8. Q2 revenue reached $282 million, with $151 million from Confluent Cloud.
8 October 2025
··
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Fifth Third’s $10.9 B Comerica Takeover Shakes Up Banking – Will Comerica Park Get a New Name?

Fifth Third Bancorp will acquire Comerica in an all-stock deal valued at $10.9 billion, creating the ninth-largest U.S. bank with about $288 billion in assets. Comerica shareholders will receive a 20% premium, and the deal is expected to close by March 2026 pending approvals. Comerica stock jumped 15% on the news, while Fifth Third shares slipped. The merger expands Fifth Third’s reach in the Midwest and Sun Belt.
6 October 2025
··
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica shares jumped as much as 15% to $81 on October 6, 2025, after Fifth Third Bancorp announced a $10.9 billion all-stock acquisition at a 20% premium. Fifth Third stock dipped 0.3%. The deal would create the ninth-largest U.S. bank with $288 billion in assets. Analysts cited regulatory tailwinds and scale benefits but warned of integration risks.
6 October 2025
···
White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

White Mountains Stock Rockets +10% on $1.75B Bamboo Deal – What Investors Need to Know

White Mountains shares surged 10.6% to $1,841.34 on Oct. 3, 2025, after announcing a $1.75 billion sale of a 77% stake in Bamboo Ide8 to CVC Capital Partners. The deal will bring WTM about $840 million in cash and boost book value per share by $310. WTM will retain roughly 15% of Bamboo. The move contrasts with a recent 2.7% drop in the S&P Insurance Index.
3 October 2025
··
1 … 17 18 19 20
Go toTop